GlassScriptPhysician profile
Sanjiv A Patel
NPI 1861564999
$41,161.21
in general payments reported to CMS, 2019-2025
29 companies · $3,408 in 2025
The $3,408 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,726 · 2020: $1,162 · 2021: $13K · 2022: $10K · 2023: $7,026 · 2024: $5,063 · 2025: $3,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $5,223 · Travel and Lodging: $36.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,237.50 |
| Food and Beverage | $5,222.71 |
| Travel and Lodging | $36.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32,825.21 | 2021-2025 | |
| Novo Nordisk INC | $2,979.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $1,574.08 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,326.02 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $514.41 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $335.03 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $247.39 | 2019-2022 | |
| Lilly USA, LLC | $197.30 | 2019 | |
| Amgen INC. | $170.03 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $150.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $137.98 | 2022-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.24 | 2019-2022 | |
| Abbott Laboratories | $119.95 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $63.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.57 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $35.83 | 2019 | |
| Corcept Therapeutics | $34.86 | 2023 | Korlym |
| Merck Sharp & Dohme LLC | $34.62 | 2019 | |
| Neurocrine Biosciences, INC. | $33.00 | 2023 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $31.99 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $25.69 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.23 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.02 | 2022 | |
| Shire North American Group INC | $19.98 | 2019 | |
| Vyera Pharmaceuticals, LLC | $19.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.96 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.95 | 2019 | |
| Radius Health, INC. | $12.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjiv Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.